Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Daniel Callahan

Physician Assistant Peachtree City, GA Physician Assistant

NPI 1265998439 CMS profile 11165366

100 Genevieve Ct Ste A, Peachtree City, GA 30269

Open in the dashboard

General payments

$7,369

423 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Callahan of Peachtree City, GA is reported in the CMS Open Payments database as having received $7,369 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,736 95
2024 General $1,532 91
2023 General $1,172 76
2022 General $1,416 74
2021 General $1,514 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Callahan
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Daniel Callahan were reported at $1,736. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Daniel Callahan Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,514 $132 $37–$438 $132
2022 $1,416 $155 $48–$522 $149
2023 $1,172 $167 $52–$557 $160
2024 $1,532 $178 $55–$600 $164
2025 $1,736 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,292 101 payments
  2. AstraZeneca Pharmaceuticals LP $856 43 payments
  3. Lilly USA, LLC $732 45 payments
  4. Novo Nordisk Inc $716 41 payments
  5. Otsuka America Pharmaceutical, Inc. $544 27 payments
  6. Pfizer Inc. $415 26 payments
  7. Axsome Therapeutics, Inc. $273 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $249 6 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $211 12 payments
  10. Lundbeck LLC $204 10 payments
  11. Other $1,876 101 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,369 423 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $679 49 payments
  2. FARXIGA $536 27 payments
  3. REXULTI $527 26 payments
  4. MOUNJARO $514 32 payments
  5. Ozempic $450 26 payments
  6. UBRELVY $427 38 payments
  7. RYBELSUS $409 24 payments
  8. NURTEC ODT Primary Care $309 14 payments
  9. AIRSUPRA $304 15 payments
  10. NURTEC ODT Pain $267 17 payments
  11. Other $4,728 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

1,615

Median for Physician Assistant: 241

Drug cost

$138,357

Median for Physician Assistant: $4,110

Branded share of claims

17.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 57 $68,891
Farxiga Dapagliflozin Propanediol Brand 52 $42,961
Jardiance Empagliflozin Brand 17 $11,742
Telmisartan Generic 46 $1,467
Rosuvastatin Calcium Generic 97 $1,315
Atorvastatin Calcium Generic 106 $720
Ipratropium Bromide Generic 26 $676
Levothyroxine Sodium Generic 46 $664
Metformin Hcl Er Metformin Hcl Brand 29 $628
Albuterol Sulfate Hfa Albuterol Sulfate Brand 32 $593

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$9,750

Medicare's payments for the services billed

Medicare patients

72

Average age 72

Services billed

348

35 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 29%
Diabetes 24%
Chronic kidney disease 24%
Depression 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $240
$240 57 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $111
  • Lundbeck LLC $77
$188 — —
VRAYLAR
  • AbbVie, Inc. $131
$131 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $117
$117 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $85
$85 52 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record